Regeneron Pharmaceuticals (REGN) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Regeneron Pharmaceuticals (REGN) do?
Regeneron Pharmaceuticals Inc (REGN) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Discovers, manufactures, and sells antibody medications treating eye diseases, inflammatory conditions, and cancer. Develops medicines internally using its proprietary genetically engineered mouse platform to produce human antibodies. It is worth $95.50B on the market and sold $16.90B over the last year.
- Market cap
- $95.50B
- P/E ratio
- 20.4×
- Annual sales
- $16.90B
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 12, 2026
Brands and businesses behind REGN
- Dupixent: Treats eczema and asthma as a prescription biologic therapy co-developed with Sanofi for recurring royalty and profit splits.
- Eylea: Treats wet macular degeneration and retinal diseases through injected medication sold directly to eye care specialists.
- Libtayo: Treats advanced skin and lung cancers by selling an intravenous monoclonal antibody therapy to oncology clinics.
- Kevzara: Treats rheumatoid arthritis through prescription self-injectable doses commercialized in partnership with Sanofi.
- Inmazeb: Treats Ebola infection through an antibody mixture supplied directly to government stockpiles and relief agencies.
REGN’s flags, in plain English
Each flag is a number from Regeneron Pharmaceuticals’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 12, 2026.
Low debt
Low debt, only 8% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Wide Gross Margin
Gross margin of 82.7% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Stupid Cash
Can pay this year's bills 3.4 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
One Big Customer
A large share of total revenue depends on collaboration profits from Dupixent and direct sales of Eylea. A large share of sales comes from a single customer. If that customer leaves or buys less, sales drop with it.
2 more green flags open with the free trial. Try it free for 7 days.
Questions about REGN
How big is Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals’ market cap is $95.50B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $16.90B: what customers paid the company over the last year, before any costs.
What is REGN’s P/E ratio?
REGN’s P/E ratio is 20.4×. Investors pay about 20.4 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with REGN?
The first risk note on the card is One Big Customer, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Regeneron Pharmaceuticals’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. REGN’s filings on SEC.gov. The Margin Monkey is research, not advice.
